Clinical Study
Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-Line Helicobacter pylori Eradication
Table 1
Demographic data and endoscopic appearances of the two patient groups.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EACM group: 7-day esomeprazole/amoxicillin/clarithromycin/metronidazole therapy; EAC group: 7-day standard esomeprazole/amoxicillin/clarithromycin/triple therapy. |